May 12th, 2014, 16.00-17.00 CET (15:00 UK, 10:00 EST)
The EMA’s announcement of a pilot project in adaptive pathways, the UK government’s Early Access to Medicines Scheme (EAMS) and the FDA’s highly-publicised Breakthrough programme demonstrate an increase in international competition for a better, faster, approval plan for the development of needed new medicines.
Featuring:
 |
 |
 |
| Richard Barker, Director, CASMI |
James Anderson, Director of EU Industry & External Partnerships, GSK |
Nathalie Seigneuret, Senior Scientific Project Manager, Innovative Medicines Initiative (IMI) |
 |
 |
|
| John Parkinson, Director of the Clinical Practice Research Datalink, MHRA |
Samantha Roberts, Head of Science Policy, Friends of Cancer Research |
|
The webinar supported by: |
||
|
|
|
 |
For more information:
Comparison of EU and USA licensing flexibilities (click to download the full table)
Read the full report from MHRA: Report of the Expert Group on innovation in the regulation of healthcare – 25 September 2013